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AbstrAct
Objectives TNFAIP3 encodes a20 that negatively 
regulates nuclear factor kappa light chain enhancer of 
activated B cells (nF-κB), the major transcription factor 
coordinating inflammatory gene expression. TNFAIP3 
polymorphisms have been linked with a spectrum of 
inflammatory and autoimmune diseases and, recently, 
loss-of-function mutations in a20 were found to cause 
a novel inflammatory disease ‘haploinsufficiency of a20’ 
(Ha20). Here we describe a family with Ha20 caused by 
a novel TNFAIP3 loss-of-function mutation and elucidate 
the upstream molecular mechanisms linking Ha20 to 
dysregulation of nF-κB and the related inflammasome 
pathway.
Methods nF-κB activation was studied in a mutation-
expressing cell line using luciferase reporter assay. 
Physical and close-proximity protein–protein interactions 
of wild-type and TNFAIP3 p.(lys91*) mutant a20 were 
analysed using mass spectrometry. nF-κB -dependent 
transcription, cytokine secretion and inflammasome 
activation were compared in immune cells of the Ha20 
patients and control subjects.
Results the protein–protein interactome of 
p.(lys91*) mutant a20 was severely impaired, 
including interactions with proteins regulating nF-κB 
activation, Dna repair responses and the nlr family 
pyrin domain containing 3 (nlrP3) inflammasome. 
the p.(lys91*) mutant a20 failed to suppress nF-κB 
signalling, which led to increased nF-κB -dependent 
proinflammatory cytokine transcription. Functional 
experiments in the Ha20 patients’ immune cells 
uncovered a novel caspase-8-dependent mechanism 
of nlrP3 inflammasome hyperresponsiveness that 
mediated the excessive secretion of interleukin-1β and 
interleukin-18.
Conclusions the current findings significantly deepen 
our understanding of the molecular mechanisms 
underlying Ha20 and other diseases associated with 
reduced a20 expression or function, paving the way for 
future therapeutic targeting of the pathway.
InTROduCTIOn
Tumour necrosis factor alpha-induced 
protein 3 (TNAP3, also known as A20), 
encoded by the TNFAIP3 gene, is a key 
negative regulator of nuclear factor kappa 
B (NF-κB) activation downstream a large 
number of immune receptors, including the 
TNF and Toll/interleukin(IL)-1 receptor 
families and the T and B cell antigen recep-
tors.1–5 A20 achieves this via its dual function 
as a ubiquitin-editing enzyme: an N-terminal 
ovarian tumour (OTU) domain removes 
activating K63-linked polyubiquitin from key 
Key messages
What is already known about this subject?
 ► a20 is a negative regulator of nuclear factor kappa B 
(nF-κB) having a key role in immune activation and 
autoimmunity.
 ► loss-of-function mutations in a20 are reported to 
lead to an inflammatory disease termed haploinsuf-
ficiency of a20 (Ha20).
What does this study add?
 ► We report a novel p.(lys91*) a20 mutation and use it 
as a model to uncover molecular mechanisms relat-
ed to the role of a20 in Ha20 development.
 ► the p.(lys91*) fails to suppress nF-κB activity and 
has severely impaired protein interactome com-
pared with the wild-type a20 in HeK cells, and caus-
es aberrant nlrP3 inflammasome responsiveness 
in patient peripheral blood mononuclear cells.
How might this impact on clinical practice?
 ► this study significantly deepens our understanding 
on the role of a20 in rheumatic diseases and may 
provide novel approaches for the development of 
therapeutic approaches.
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intermediate NF-κB signalling molecules to destabilise 
protein–protein interactions, whereas a C-terminal zinc 
finger domain catalyses the attachment of K48-linked 
polyubiquitin to induce proteasomal degradation.3 6 7 In 
addition, A20 inhibits NF-κB activation via a non-cata-
lytic mechanism involving its binding to linear ubiquitin 
on NF-κB essential modulator (NEMO).8 9 The mRNA 
expression of A20 is NF-κB-inducible,10 thus generating 
a negative feedback loop to attenuate NF-κB responses.
Recently Zhou et al reported six families with hetero-
zygous loss-of-function mutations in the TNFAIP3 gene 
that led to haploinsufficiency of A20 (HA20) and caused 
an early-onset Behçet-like disease.11 Studies in mouse 
models have previously demonstrated a crucial role for 
A20 in autoinflammation and autoimmunity as mice with 
a germline deletion of Tnfaip3 spontaneously develop 
severe multiorgan inflammation and tissue damage 
resulting in perinatal death,12 and cell-specific ablation 
of Tnfaip3 results in diverse symptoms of immune dysreg-
ulation.13 14 Similar to Tnfaip3 deficiency in mice,12–15 
human HA20 led to exaggerated NF-κB responses 
and increased secretion of NLR family pyrin domain 
containing 3 (NLRP3) inflammasome target cytokines.11 
Additional reports from these16 and further identified 
patients17–21 have expanded the clinical spectrum of 
HA20 to comprise diseases such as autoimmune lymph-
oproliferative syndrome, systemic juvenile arthritis, psori-
atic arthritis, Crohn’s disease and Hashimoto’s thyroiditis. 
The increasing number of diseases associated with A20 
has emphasised its role in inflammatory diseases and in 
autoimmunity and raised the possibility that mutations in 
TNFAIP3 may be an unexpectedly common underlying 
factor in the pathogenesis of rheumatic and other auto-
immune diseases.
We describe here a family with polyautoimmunity and 
autoinflammatory symptoms caused by a novel hetero-
zygous TNFAIP3 p.(Lys91*) loss-of-function mutation 
resulting in haploinsufficiency. Our aim was to further 
elucidate the upstream molecular mechanisms linking 
HA20 to dysregulated NF-κB activation and NLRP3 
inflammasome responses. Thus, we analysed protein–
protein interactions of wild-type (wt) and p.(Lys91*) A20 
in HEK cells and performed functional experiments in 
patients’ immune cells to study NLRP3 inflammasome 
responses. As A20 is rapidly emerging as a key regulator 
of immune activation and autoimmunity in humans, the 
detailed characterisation of A20 effector mechanisms 




DNA samples were extracted from total peripheral blood 
using standard methods. Whole-exome sequencing and 
data analysis were performed as previously described.22 23 
All the common (frequencies >0.01 in the general popu-
lation) and non-coding variants were discarded. We 
searched for rare heterozygous variants, according to 
the inferred autosomal-dominant inheritance pattern 
(figure 1A). The variant identified in the TNFAIP3 
gene (Ensembl ENSG00000118503:ENST00000433680: 
exon2:c.A271T: p.(Lys91*) was confirmed using PCR 
and capillary electrophoresis.
Creating a20 expressing Flp-In 293 T-Rex cell lines
A20 mutant plasmids were created using QuickChange 
Site-Directed Mutagenesis kit (Agilent Technologies) to 
wt TNFAIP3 obtained from the human Orfeome collec-
tion (Horizon Discovery). TNFAIP3 constructs were 
further subcloned into N-terminal MAC-tag Gateway 
destination vector.24 All generated constructs were 
confirmed with direct sequencing. The MAC-tagged 
expression constructs were transfected into Flp-In 
293 T-REx cells (Invitrogen, Life Technologies) 
with FuGENE HD (Promega). The cells were grown 
according to manufacturer’s instructions under selec-
tion with Hygromycin B (Thermo Fisher Scientific) 
to create stable cell lines. Expression of stable trans-
genes was confirmed by western blotting using anti-he-
magglutin (HA) primary (Biolegend, MMS-101R) and 
horseradish peroxidase-conjugated secondary anti-
body.
luciferase assay
For reporter assays, HEK293 cells were transfected with 
in total 50 ng A20 mutant or wt MAC-tagged construct 
and GFP or empty MAC-tag-vector,24 40 ng of NF-κB lucif-
erase reporter plasmid (Cignal 45), and 1.4 ng Renilla 
luciferase reporter plasmid (pRL-SV40). Transfected 
cells were stimulated with indicated amounts of tumour 
necrosis factor alpha TNF-α (R&D Systems) for 16 hours, 
lysed with 1× passive lysis buffer (Promega) and luciferase 
assays performed with Dual-Glo Luciferase Assay System 
according to manufacturer’s instructions (Promega).
affinity purification and mass spectrometry
For each pull-down approximately 5×107 cells (5×15 cm 
dishes) were induced with 2 µg/mL tetracycline (Thermo 
Fisher Scientific) for 24 hours (for BioID additional 50 
µM biotin was added). After induction, cells were washed, 
harvested, pelleted by centrifugation, snap-frozen and 
stored at −80°C until analysis. Affinity purification of 
AP-MS and BioID was performed as described in Turunen 
et al 25 and Heikkinen et al,26 respectively. Sample prepa-
ration for mass spectrometry and LC-MS/MS analysis on 
Orbitrap Elite ETD mass spectrometer was performed as 
in Heikkinen et al.26 After peptide reconstitution, 4 µL was 
analysed from both Strep-Tag and BioID-samples.
Culture and stimulation of peripheral blood mononuclear cells 
(PBMCs)
PBMCs were isolated by density gradient centrifugation in 
Ficoll-Paque PLUS (GE Healthcare) and seeded at 1.5×106 
cells/mL in Macrophage-SFM medium supplemented with 
penicillin-streptomycin or in RPMI 1640 supplemented 
with GlutaMAX, penicillin-streptomycin and 10% FBS (all 
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Figure 1 Phenotypic and protein-level characteristics of a family with newly identified TNFAIP3 c.A271T: p.(Lys91*) mutation. 
(A) A pedigree showing the TNFAIP3 p.(Lys91*) mutation carriers (–/+, solid symbols) in three generations (I–III). Autoimmune 
thyroiditis was diagnosed in all carriers (I-2, II-1, II-4, III-1) at an early age. In addition, the index patient (II-1) suffered from 
psoriasis, articular symptoms, atrophic gastritis, severe autoinflammatory lung reaction, anaemia, genital papillomatosis and 
repeated genital HSV infections. Daughter of the index (III-1) was diagnosed with polyarticular juvenile idiopathic arthritis at 
the age of 4 years, and mother of the index (I-2) died of liver failure at the age of 46 years. (B) Schematic illustration of A20 
structure showing the protein domains (upper panel) and the folding (lower panel). Position of the novel p.(Lys91*) mutation 
is indicated in blue. (C) 3D structure models of wild-type and mutant p.(Lys91*) A20 (based on PDB accession 5LRX). OTU 
domain is highlighted with pink. HSV, herpes simplex virus; OTU, ovarian tumour.
from Gibco). PBMCs were allowed to rest for a minimum 
of 3 hours before starting the stimulations with 1 µg/mL 
lipopolysaccharides (LPS) from Escherichia coli O111:B4 
(Sigma), 1 µg/mL Pam3Cys-SKKKK (Pam3Cys; EMC micr-
ocollections), 10 µg/mL polyinosinic-polycytidylic acid 
(poly(I:C); InvivoGen) and 5 mM adenosine 5′-triphos-
phate (ATP; Sigma) for the indicated times. Inhibitors 
Z-YVAD-FMK (20 µM; R&D Systems), Z-IETD-FMK (5 
µM; BD Bioscience) and necrostatin-1 (30 µM; Enzo Life 
Sciences) were added to the cells simultaneously with LPS 
in the 16-hour stimulations or 30 min before LPS in the 
LPS 6 hour+ATP 45 min stimulations.
Measurement of cytokine secretion
TNF-α and the mature, cleaved forms of interleukin 
(IL)-1β and IL-18 were detected from PBMC culture media 
supernatants using Human TNF-α DuoSet ELISA, Human 
IL-1β/IL-1F2 DuoSet ELISA and Human Total IL-18 
DuoSet ELISA (all from R&D Systems).
Quantitative real-time PCR
RNA was isolated from PBMCs using RNeasy Plus Mini Kit 
(Qiagen) and cDNA synthesised with iScript kit (Bio-Rad). 
Quantitative real-time PCR was performed from 10 ng of 
cDNA per reaction using LightCycler480 SYBR Green I 
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master (Roche) and LightCycler96 instrument (Roche); 
primer sequences are listed in online supplementary table 
1. Relative gene expression was calculated using the 2(-ΔΔCt) 
method, normalising to the geometric mean of expression 
of two housekeeping genes, ribosomal protein lateral stalk 
subunit P0 and beta-2 microglobulin.
Monocyte caspase-1 activity measurement
Aliquots of EDTA-anticoagulated blood were incubated 
for 6 hours at +37°C under gentle rocking with or without 
10 ng/mL LPS (Sigma). ATP at 5 mM (Sigma) was added 
for 20 min, followed by 2-hour incubation at +37°C with 
a cell-permeable, irreversibly binding FAM-FLICA fluores-
cent caspase-1 substrate (ImmunoChemistry Technolo-
gies). After red blood cell lysis and staining with the mono-
cyte marker anti-human CD14-APC (Miltenyi Biotec) for 
15 min at +4°C, the cells were analysed using BD Accuri C6 
flow cytometer (BD Biosciences; instrument maintained by 
the Biomedicum Flow Cytometry Unit).
ResulTs
Identification of the mutation and the clinical manifestations 
of the patients
Exome sequencing of the index patient (II-1) identi-
fied a novel nonsense mutation in the exon 2 of the 
TNFAIP3 gene: c.A271T: p.(Lys91*) (ENSG000001185
03:ENST00000433680) (figure 1A,B). The mutation is 
not listed in Genome Aggregation Database (gnomAD, 
Cambridge, Massachusetts, USA) and was predicted to be 
pathogenic according to the ACMG Standards and Guide-
lines.27 The TNFAIP3 p.(Lys91*) mutation was confirmed 
in the patient’s genomic DNA and screened in the other 
members of the family. Two other affected family members 
(II-4, III-1) were observed to also harbour the mutation, 
(I-2 is an obligate carrier). The clinical manifestations of 
the carriers included autoimmune thyroiditis, which was 
diagnosed in all carriers (I-2, II-1, II-4, III-1) at an early age. 
The index patient suffered from psoriasis, articular symp-
toms, atrophic gastritis, severe inflammatory lung reaction, 
anaemia and repeated genital HSV infections. Daughter 
of the index was diagnosed with polyarticular juvenile 
idiopathic arthritis at the age of 4. See also the legend of 
figure 1A.
effect of the TnFaIP3 p.(lys91*) mutation on protein structure 
and expression
The 3D protein structures of wt and p.(Lys91*) A20 were 
visualised by processing the PDB (http://www. rcsb. org28) 
accession number 5LRX (chain A29 with Chimera,30 which 
yielded a severely truncated protein lacking the complete 
OTU domain (figure 1C). To further analyse the expres-
sion and possible physical and functional changes caused 
by the TNFAIP3 p.(Lys91*) mutation, stable Flp-In 293 
T-REx cell lines expressing wt and p.(Lys91*) A20 were 
created. The wt HA-tagged A20 was expressed in western 
blot, but the p.(Lys91*) mutant was detected only with an 
N-terminal tag (figure 2A), suggesting that only an N-ter-
minal fragment is produced and no alternative start codons 
are used. Peptide identification using mass spectrometry 
confirmed that only the N-terminal region was detectable in 
the p.(Lys91*) mutant (figure 2B). The expression levels of 
the N-terminal peptides/protein of the wt and p.(Lys91*) 
mutant A20 were highly comparable (figure 2B).
a20 p.(lys91*) mutant fails to suppress nF-κB activation and 
shows severely impaired protein–protein interactome
To analyse the possible functional consequences of the 
p.(Lys91*) mutation and the loss of OTU domain on the 
A20 functions, we monitored the NF-κB pathway activity 
using a luciferase-based reporter assay. The wt A20 dose-de-
pendently inhibited TNF-α induced NF-κB pathway activa-
tion, whereas the p.(Lys91*) mutant failed to do so, clearly 
suggesting a haploinsufficiency (figure 2C).
The physical effects of the p.(Lys91*) mutation were 
further analysed by proteome-wide affinity purification mass 
spectrometry (AP-MS) (see online supplementary figure 1 
for details). These analyses revealed that the p.(Lys91*) 
mutant completely loses physical interactions with BRCC3, 
TRAD1, WRIP1, TRAF2, BIRC2, F175B, USP9X and 
HUWE1, with several additional weakened interactions 
(figure 2D). To obtain more insight into the molecular 
mechanisms of A20 and especially on the p.(Lys91*) muta-
tion, we further quantitatively analysed the functional and 
close-proximity interactions using BioID MS24 (see online 
supplementary figure 1 for details). This analysis revealed 
complete loss of interactions with AZI2, TNIP1, TBK1, 
CYLD, CCD50, SLK, ITSN1, HAUS6, OGA, SH3K1, WDCP, 
TRIM9, PDLI1, FHL3, KPYM, COPE, UBA1, CE152 and 
PGK1. Many more interactions were severely diminished 
(figure 2D). Majority of the detected interactions of wt 
A20 were novel (figure 3). Functional annotation revealed 
extensive interactions with ubiquitinylation-related, prote-
asome-related and NF-κB-related proteins, as well as with 
proteins involved, for example, in cell fate decisions (14-3-3 
proteins), DNA repair (53BP1 complex) and glycolysis 
(figure 3). Of these, the interactions with ubiquitinyla-
tion-related and NF-κB-related proteins were most severely 
affected in the A20 p.(Lys91*) mutant.
Blood immune cells of TnFaIP3 p.(lys91*) carriers display 
strongly increased secretion of inflammasome-controlled 
cytokines Il-1β and Il-18
The NF-κB pathway and A20 have been shown to play regu-
latory roles in the activation of NLRP3 inflammasome, a 
pathway triggering caspase-1-mediated proteolytic matu-
ration and secretion of proinflammatory cytokines IL-1β 
and IL-18.15 31 32 Excessive NLRP3-dependent cytokine 
secretion was demonstrated in HA20,11 yet the mecha-
nism(s) linking reduced A20 to NLRP3 inflammasome acti-
vation in patient cells were not elucidated. We stimulated 
PBMCs of the HA20 patients with Toll-like receptor (TLR) 
4 agonist LPS, with or without a subsequent ATP pulse; 
both stimuli trigger the NLRP3 inflammasome in mono-
cytes via distinct mechanisms and with different kinetics.31 
We found elevated secretion of IL-1β and IL-18 in PBMCs 
of the TNFAIP3 p.(Lys91*) carriers in response to LPS 
+ATP-induced ‘canonical’ (figure 4A,B; left panels) as well 
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Figure 2 The p.(Lys91*) mutant A20 fragment is expressed but shows severe impairment of protein–protein interactions and 
of inhibitory activity on nuclear factor (NF)-κB signaling. (A) Expression profile analysis of wild type (wt) A20 and the p.(Lys91*) 
mutant in HEK293 cells. The wt protein is detected with both as N- and C-terminally tagged constructs, whereas the p.(Lys91*) 
mutant is only detected as N-terminally tagged illustrating that no alternative start site is used and only short N-terminal 
fragment is produced. (B) Quantitative mass spectrometry-based proteomics analysis shows that the N-terminal part of the 
wt A20 and p.(Lys91*) mutant are expressed in similar levels as shown by the quantitative abundance of the peptides derived 
from the N-termini. (C) wt A20 dose-dependently inhibits the NF-κB signaling induced by tumour necrosis factor alpha 
(TNF-α) (light green=10 ng/mL and dark green=25 ng/mL), whereas the p.(Lys91*) mutant shows clearly diminished inhibitory 
activity suggesting haploinsufficiency. The asterisks represent the significance values; *<0.05, ** <0.01, *** <0.001. (D) Affinity 
purification mass spectrometry (AP-MS) (upper panel) and BioID (lower panel) analysis of wt and p.(Lys91*) mutant A20 show 
clear differences in their stable protein–protein interactions and BioID analysis displays differential molecular context of the 
p.(Lys91*) mutant compared with the wt A20. (The size and the colour gradient shows the relative abundance of the interacting 
prey protein detected in association with A20, red typeface designates the complete loss of the corresponding interactions and 
yellow >50% decrease compared with the wt A20).
as LPS-induced ‘alternative’ pathway of NLRP3 inflam-
masome activation (figure 4A,B; right panels). To control 
for potential confounding factors in FBS preparations, 
PBMC cytokine secretion was analysed both in commer-
cial serum-free monocyte-macrophage medium (figure 4) 
and in RPMI containing 10% FBS (online supplementary 
figure 2), yielding similar results. Also, TNF-α secretion in 
response to LPS, Pam3Cys and poly(I:C) was increased in 
the patients (figure 4C, online supplementary figure 2C. 
We further studied the levels of IL-1β and IL-18 in patients’ 
plasma by ELISA and found increased levels of circulating 
IL-18 in TNFAIP3 p.(Lys91*) carriers compared with the 
age-matched and sex-matched controls (online supple-
mentary figure 3A), whereas IL-1β was not detectable.
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Figure 3 Interactome analysis reveals known and novel interactions for A20. Affinity purification mass spectrometry and BioID 
analysis of A20 identified 98 high-confidence protein–protein interactions (known interactions are shown with green lines, novel 
interaction detected on this study with blue and known prey–prey interactions with a dashed line). The interacting proteins are 
grouped based on their molecular functions/complexes. Interactions, which are lost with the p.(Lys91*) mutation, are illustrated 
with red node fill colour.
The increased nlRP3 inflammasome response in TnFaIP3 
p.(lys91*) carriers is dependent on enhanced pro-Il-1β 
transcription and caspase-8 activity, but not on RIPK1
To elucidate the mechanism of altered NLRP3 inflam-
masome activation in the HA20 patients’ PBMCs, 
we analysed the mRNA expression of inflammasome 
pathway components and cytokines and the effect of 
inflammasome-related inhibitors on cytokine secretion. 
PBMCs of patient III-1 displayed strongly increased 
baseline expression of pro-IL-1β and NLRP3 receptor, 
whereas patient II-1 cells showed only moderate 
changes (online supplementary figure 3B). After LPS 
stimulation, PBMCs from both patients showed slightly 
elevated levels of pro-IL-1β mRNA and NLRP3 receptor 
expression remained moderately elevated only in 
patient III-1 (figure 5A). LPS-induced expression of 
NF-κB target cytokines IL-6, TNF-α and IL-8 was elevated 
in patient III-1, and IL-6 also in patient II-1 (figure 5B). 
Receptor interacting serine/threonine-protein kinase 1 
(RIPK1) inhibitor necrostatin-1 did not affect IL-1β or 
IL-18 secretion in the patients’ PBMCs (figure 4A,B), 
although it normalised the excessive TNF-α response 
to 16-hour LPS treatment (figure 4C, right panel). 
As expected, both canonical and alternative NLRP3 
inflammasome responses were efficiently blocked by 
the caspase-1 inhibitor Z-YVAD-FMK (figure 4A,B). 
However, levels of active caspase-1 in monocytes after 
whole blood inflammasome stimulation were increased 
only in patient II-1 (figure 5C), supporting a more 
indirect enhancement of inflammasome complex func-
tion. Remarkably, caspase-8 inhibitor Z-IETD-FMK effi-
ciently suppressed IL-1β and IL-18 secretion in PBMCs 
of the TNFAIP3 p.(Lys91*)-positive patients, particu-
larly after canonical NLRP3 inflammasome activation 
(figure 4A,B).
dIsCussIOn
HA20 is a recently described familial autoinflamma-
tory disease originally reported to manifest as an early-
onset Behçet-like disease,11 yet the range of known clin-
ical manifestations is rapidly expanding.16–21 Here we 
studied patients with HA20 caused by a novel heterozy-
gous TNFAIP3 p.(Lys91*) mutation resulting in severe 
truncation and production of an N-terminal protein 
fragment with highly limited functional capacity. The 
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Figure 4 Inflammasome-dependent and inflammasome-independent proinflammatory cytokine secretion is elevated in 
peripheral blood mononuclear cells (PBMCs) of TNFAIP3 p.(Lys91*) carriers. PBMCs from TNFAIP3 p.(Lys91*) mutation carriers, 
patients 1 (II-1, woman, 30 years) and 2 (III-1, female, 8 years), were compared with sex-matched and age-matched controls 
1 and 2, respectively. (A–C, left panels) The cells were primed with LPS for 6 hours, followed by treatment with ATP for 45 min. 
(A–C, right panels) The cells were treated with TLR agonists for 16 hours. Inhibitors necrostatin-1 (nec), Z-YVAD-FMK (yvad) 
and Z-IETD-FMK (ietd), or solvent control dimethyl sulfoxide (dmso) were added as indicated and cytokines were detected from 
PBMC culture supernatants by ELISAs. IL, interleukin; TNF, tumour necrosis factor; LPS, lipopolysaccharide.
patients exhibit an unusual combination of early-onset 
autoimmune diseases, autoinflammatory symptoms and 
immunodeficiency, reflecting the widespread functions 
of A20 in controlling inflammation. To gain further 
insight into the molecular mechanism underlying 
the development of this complex disease, we focused 
on scrutinising two pathways strongly linked with A20 
function; the NF-κB pathway and the NLRP3 inflam-
masome.
Mutations causing HA20 were previously reported to 
increase TNF-α-induced IKKα/IKKβ and MAPK phos-
phorylation and activation of NF-κB via defective removal 
of K63-linked ubiquitin from RIPK1, TNF receptor-as-
sociated factor 6 and NEMO.11 18 19 As expected, also 
the A20 p.(Lys91*) mutant was defective in suppressing 
TNF-α-induced NF-κB activation. We employed state-of-
the-art proteomics tools to comprehensively map global 
changes in A20 protein–protein interactions caused 
by the p.(Lys91*) mutation. In agreement with A20 
ubiquitin-editing functions, the results revealed loss 
of physical interactions with ubiquitin ligases (BIRC2, 
TRAF2, HUWE1), deubiquitinases (BRCC3, USP9X) 
and other ubiquitinylation modulators (WRIP1 and 
F175B/ABRX2). BIRC2/3 and TRAF2/3 form a regu-
latory complex that suppresses apoptotic functions of 
caspase-8 to enforce canonical (inflammatory) NF-κB 
signalling, while blocking non-canonical NF-κB activa-
tion.33 34 A20 modulates this balance by inducing TRAF2 
degradation to suppress canonical NF-κB activation, 
and by binding c-IAP1/2 to support their caspase-8-in-
hibiting function while blocking their noncanon-
ical NF-κB-inhibiting function.35–37 Thus, the loss of 
A20 p.(Lys91*) interaction with BIRC2 and TRAF2 is 
compatible with enhancement of caspase-8 activity and 
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Figure 5 Expression and activation of the NLRP3 inflammasome is altered in peripheral blood mononuclear cells (PBMCs) of 
TNFAIP3 p.(Lys91*) carriers. Samples from TNFAIP3 p.(Lys91*) mutation carriers, patients 1 (II-1, woman, 30 years) and 2 (III-1, 
female, 8 years), were compared with sex-matched and age-matched controls 1 and 2, respectively. Relative expression of (A) 
NLRP3 inflammasome components and target cytokines and (B) inflammasome-independent proinflammatory cytokines was 
analysed in PBMCs by quantitative PCR and normalised against housekeeping gene expression (arbitrary units). (C) Whole 
blood was stimulated with LPS and ATP, followed by the detection of NLRP3 inflammasome-triggered caspase-1 activity in 
monocytes using a fluorescent FLICA probe; the data are presented as median fluorescence intensity (MFI).
canonical NF-κB signalling. In turn, BRCC3, F175B/
ABRX2, WRIP1 and HUWE1 have specific functions in 
DNA damage responses,38–41 which could be a signifi-
cant finding regarding the association of reduced A20 
levels with systemic lupus characterised by autoanti-
bodies against nuclear antigens.14 Moreover, BRCC3 
and F175B/ABRX2 are also components of the BRISC 
deubiquitinase complex that cleaves K63-linked ubiq-
uitin and regulates mitotic spindle assembly,42 type 
I interferon signalling43 and NLRP3 inflammasome 
activation.44 Also, functional close-proximity protein–
protein interactions of the A20 p.(Lys91*) mutant, 
particularly those related to ubiquitinylation and NF-κB 
signalling, were severely impaired, whereas interac-
tions with proteasome, 53BP1-containing DNA repair 
complex and 14-3-3 regulatory proteins remained 
partially functional.
The roles of A20 in regulation of the NLRP3 inflam-
masome, both NF-κB-dependent and NF-κB-inde-
pendent, are just beginning to be uncovered.15 32 
Mice deficient in myeloid A20 develop erosive poly-
arthritis specifically due to poor control of NLRP3 
inflammasome activation by A20.15 Moreover, increased 
NLRP3-dependent secretion of IL-1β and IL-18 was 
reported in HA20 patients,11 17 yet the upstream mech-
anism(s) linking this effect to A20 in patient immune 
cells remain unknown. We found increased IL-1β and 
IL-18 secretion in PBMCs of TNFAIP3 p.(Lys91*)-posi-
tive patients in response to both canonical and alterna-
tive NLRP3-activating stimuli. In mouse macrophages, 
A20 suppresses the NF-κB-induced mRNA expression 
of NLRP3 receptor and pro-IL-1β, but also blocks 
RIPK1/3-dependent pro-IL-1β ubiquitination that 
supports the inflammasome-mediated processing into 
mature IL-1β.15 32 Our patients’ PBMCs showed elevated 
LPS-induced transcription of pro-IL-1β, but NLRP3 
receptor expression was not consistently increased. 
The RIPK1 inhibitor necrostatin-1 that reduced aber-
rant IL-1β secretion in Tnfaip3-deficient mouse macro-
phages32 had no effect on IL-1β nor IL-18 secretion 
in the patients’ PBMCs, which was, instead, strongly 
suppressed by caspase-8 inhibition. This suggests a 
novel caspase-8-dependent mechanism linking reduced 
A20 function to enhanced NLRP3 inflammasome 
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activation. The finding is in line with the increased 
caspase-8 activity reported in Tnfaip3-deficient mouse 
cells32 45 and with the caspase-8-suppressing functions 
of A20,37 45 and further supported by the loss of phys-
ical interaction between A20 p.(Lys91*) mutant and 
BIRC2, which is required for caspase-8 inhibition by 
A20.37 Previous studies suggest that alongside its apop-
totic functions caspase-8 facilitates the priming and 
activation of NLRP3 inflammasome via multiple mech-
anisms.46 In addition, the loss of interaction between 
A20 p.(Lys91*) mutant and the BRCC3-containing 
BRISC complex suggests a further novel NLRP3-regu-
lating function of A20 that is lost in haploinsufficient 
cells, as BRCC3 deubiquitinates the NLRP3 receptor 
directly promoting its activation.44
In summary, we report here a TNFAIP3 p.(Lys91*) 
loss-of-function mutation leading to HA20 and autoim-
mune/inflammatory symptoms. We use this mutation 
as a model to uncover novel molecular mechanisms 
related to the role of A20 in disease development. We 
defined, for the first time, the global physical and func-
tional interactome of wt A20 and found severely dimin-
ished interactions in the p.(Lys91*) mutant. Moreover, 
we discovered a novel caspase-8-dependent mechanism 
linking HA20 to hyperactivation of the NLRP3 inflam-
masome in patient immune cells. Collectively, these 
data greatly deepen our understanding of the molecular 
mechanisms underlying the clinical disease phenotype 
of HA20 and other diseases associated with reduced 
A20 expression or function. We believe that defining 
the physical and functional interaction changes in (m)
any diseases is highly usable for understanding these 
diseases better on the molecular level and believe such 
studies will be seen in immense quantity in the near 
future.
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